David C Fajgenbaum (David Fajgenbaum)

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 45

Top Venues

British journal of haematology

American journal of hematology

Blood advances

Blood

University of Pennsylvania

University of Oxford (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Pennsylvania

United States

Assistant Professor :: Medicine, Division of Translational Medicine & Human Genetics

Education History

University of Oxford

United Kingdom

MSC :: Public Health

Georgetown University

United States

BSC :: Human Sciences

Publications

Ayelet I Rubenstein, Sheila K Pierson, Saishravan Shyamsundar, Mateo Sarmiento Bustamante, Michael V Gonzalez, Ira D Milller, Joshua D Brandstadter, Melanie D Mumau, David C Fajgenbaum
Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease. British journal of haematology 204 (3) (2024)
Ayelet I Rubenstein, Sheila K Pierson, Saishravan Shyamsundar, Mateo Sarmiento Bustamante, Michael V Gonzalez, Ira D Milller, Joshua D Brandstadter, Melanie D Mumau, David C Fajgenbaum
Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease. British journal of haematology 204 (3) (2024)
Frits van Rhee, David C Fajgenbaum
Insights into the etiology of Castleman disease. Blood 143 (18) (2024)
Ayelet I Rubenstein, Sheila K Pierson, Saishravan Shyamsundar, Mateo Sarmiento Bustamante, Michael V Gonzalez, Ira D Milller, Joshua D Brandstadter, Melanie D Mumau, David C Fajgenbaum
Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease. British journal of haematology 204 (3) (2024)
Asami Nishikori, Midori Filiz Nishimura, David C Fajgenbaum, Yoshito Nishimura, Kanna Maehama, Tomoka Haratake, Tetsuya Tabata, Mitsuhiro Kawano, Naoya Nakamura, Shuji Momose, Remi Sumiyoshi, Tomohiro Koga, Hidetaka Yamamoto, Frits Van Rhee, Atsushi Kawakami, Yasuharu Sato
Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): Factors to differentiate from IgG4-related disease. Journal of clinical pathology (2024)
Asami Nishikori, Midori Filiz Nishimura, David C Fajgenbaum, Yoshito Nishimura, Kanna Maehama, Tomoka Haratake, Tetsuya Tabata, Mitsuhiro Kawano, Naoya Nakamura, Shuji Momose, Remi Sumiyoshi, Tomohiro Koga, Hidetaka Yamamoto, Frits Van Rhee, Atsushi Kawakami, Yasuharu Sato
Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): Factors to differentiate from IgG4-related disease. Journal of clinical pathology (2024)
Frits van Rhee, David C Fajgenbaum
Insights into the etiology of Castleman disease. Blood 143 (18) (2024)
Ayelet I Rubenstein, Sheila K Pierson, Saishravan Shyamsundar, Mateo Sarmiento Bustamante, Michael V Gonzalez, Ira D Milller, Joshua D Brandstadter, Melanie D Mumau, David C Fajgenbaum
Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease. British journal of haematology (2024)
Yu-Han Gao, Yan-Ting Liu, Miao-Yan Zhang, Si-Yuan Li, David C Fajgenbaum, Lu Zhang, Jian Li
Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival. British journal of haematology 204 (5) (2024)
Ayelet I Rubenstein, Sheila K Pierson, Saishravan Shyamsundar, Mateo Sarmiento Bustamante, Michael V Gonzalez, Ira D Milller, Joshua D Brandstadter, Melanie D Mumau, David C Fajgenbaum
Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease. British journal of haematology 204 (3) (2024)
Yu-Han Gao, Yan-Ting Liu, Miao-Yan Zhang, Si-Yuan Li, David C Fajgenbaum, Lu Zhang, Jian Li
Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival. British journal of haematology 204 (5) (2024)
Christian Hoffmann, Eric Oksenhendler, Sarah Littler, Lisa Grant, Karan Kanhai, David C Fajgenbaum
The clinical picture of Castleman disease-a systematic review and meta-analysis. Blood advances (2024)
Ayelet I Rubenstein, Sheila K Pierson, Saishravan Shyamsundar, Mateo Sarmiento Bustamante, Michael V Gonzalez, Ira D Milller, Joshua D Brandstadter, Melanie D Mumau, David C Fajgenbaum
Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease. British journal of haematology 204 (3) (2024)
Asami Nishikori, Midori Filiz Nishimura, David C Fajgenbaum, Yoshito Nishimura, Kanna Maehama, Tomoka Haratake, Tetsuya Tabata, Mitsuhiro Kawano, Naoya Nakamura, Shuji Momose, Remi Sumiyoshi, Tomohiro Koga, Hidetaka Yamamoto, Frits Van Rhee, Atsushi Kawakami, Yasuharu Sato
Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): Factors to differentiate from IgG4-related disease. Journal of clinical pathology (2024)
Madelaine Beckett, Caroline Spaner, Mariam Goubran, John Wade, Juan Antonio Aviña-Zubieta, Audi Setiadi, Lori B Tucker, Kamran Shojania, Sheila Au, Andre Mattman, Agnes Y Y Lee, David C Fajgenbaum, Luke Y C Chen
CRP and sCD25 help distinguish between adult-onset Still's disease and HLH. European journal of haematology (2024)
Yu-Han Gao, Yan-Ting Liu, Miao-Yan Zhang, Si-Yuan Li, David C Fajgenbaum, Lu Zhang, Jian Li
Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival. British journal of haematology (2024)
Yu-Han Gao, Yan-Ting Liu, Miao-Yan Zhang, Si-Yuan Li, David C Fajgenbaum, Lu Zhang, Jian Li
Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival. British journal of haematology (2024)
Natalie A Mango, Sheila K Pierson, Mateo Sarmiento Bustamante, Joshua D Brandstadter, Frits Van Rhee, David C Fajgenbaum
Siltuximab administration results in spurious IL-6 elevation in peripheral blood. American journal of hematology (2023)
Sheila K Pierson, Megan S Lim, Gordan Srkalovic, Joshua D Brandstadter, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Natalie Mango, Criswell Lavery, Bridget Austin, Daisy Alapat, Mary Jo Lechowicz, Adam Bagg, Honzhe Li, Corey Casper, Frits van Rhee, David C Fajgenbaum
Treatment Consistent with Idiopathic Multicentric Castleman Disease Guidelines is Associated with Improved Outcomes. Blood advances (2023)
Joshua D Brandstadter, Angelina De Martin, Mechthild Lütge, Antonio Ferreira, Brian T Gaudette, Yves Stanossek, Shumei Wang, Michael V Gonzalez, Edward Camiolo, Gerald Wertheim, Bridget Austin, David Allman, Megan S Lim, David C Fajgenbaum, Jon C Aster, Burkhard Ludewig, Ivan P Maillard
A novel cryopreservation and biobanking strategy to study lymphoid tissue stromal cells in human disease. bioRxiv : the preprint server for biology (2023)
Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Freda R Coren, Adam Bagg, Gordan Srkalovic, Daisy Alapat, Frits Van Rhee, Megan S Lim, Mary Jo Lechowicz, Joshua D Brandstadter, Sheila K Pierson, David C Fajgenbaum
Ongoing symptoms following complete surgical excision in unicentric Castleman disease. American journal of hematology (2023)
Amanallah Montazeripouragha, Christine M Campbell, James Russell, Nadia Medvedev, Daniel R Owen, Alison Harris, Fergal Donnellan, Iain McCormick, David C Fajgenbaum, Luke Y C Chen
Thrombocytopenia, anasarca, and severe inflammation. American journal of hematology 97 (10) (2022)
David C Fajgenbaum, Adrian C Hayday, Angela J Rogers, Greg J Towers, Andreas Wack, Ivan Zanoni
Anti-type I interferon antibodies as a cause of severe COVID-19. Faculty reviews 11 (2022)
Sudipto Mukherjee, Karan Kanhai, David Kauffman, Rabecka Martin, Jeremy S Paige, Anirvan Ghosh, Hannah Kannan, Francis Shupo, David C Fajgenbaum
Correction to: Organ dysfunction, thrombotic events, and malignancies in patients with idiopathic multicentric Castleman disease: a population-level US health claims analysis. Leukemia (2022)
Ertugrul Bayram, Umur Anıl Pehlivan, David C Fajgenbaum, Semra Paydaş
Refractory idiopathic multicentric Castleman disease responsive to sirolimus therapy. American journal of hematology (2022)
Sheila K Pierson, Laura Katz, Reece Williams, Melanie D Mumau, Michael Gonzalez, Stacy Guzman, Ayelet Rubenstein, Ana B Oromendia, Philip Beineke, Alexander Fosså, Frits Van Rhee, David C Fajgenbaum
CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease. Nature communications 13 (1) (2022)
Elizaveta Belyaeva, Ayelet Rubenstein, Sheila K Pierson, Delaney Dalldorf, Dale M Frank, Megan S Lim, David C Fajgenbaum
Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review. Hematological oncology 40 (2) (2022)
Sudipto Mukherjee, Karan Kanhai, David Kauffman, Rabecka Martin, Jeremy S Paige, Anirvan Ghosh, Hannah Kannan, Francis Shupo, David C Fajgenbaum
Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease: a population-level US health claims analysis. Leukemia 36 (10) (2022)
Lu Zhang, Miao-Yan Zhang, Xin-Xin Cao, Dao-Bin Zhou, David C Fajgenbaum, Yu-Jun Dong, Jian Li
A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD. Leukemia & lymphoma 63 (3) (2022)
Alexis D Phillips, Joseph J Kakkis, Patricia Y Tsao, Sheila K Pierson, David C Fajgenbaum
Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO. Journal of cellular and molecular medicine 26 (11) (2022)
David C Fajgenbaum, Sheila K Pierson, Karan Kanhai, Adam Bagg, Daisy Alapat, Megan S Lim, Mary Jo Lechowicz, Gordan Srkalovic, Thomas S Uldrick, Frits van Rhee, null null
The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry. British journal of haematology 198 (2) (2022)
David C Fajgenbaum, Reece J Goiffon, Jacob D Soumerai, Cynthia K Harris
Case 16-2022: A 55-Year-Old Man with Fevers, Night Sweats, and a Mediastinal Mass. The New England journal of medicine 386 (21) (2022)
Sheila K Pierson, Sushila Shenoy, Ana B Oromendia, Alexander M Gorzewski, Ruth-Anne Langan Pai, Christopher Shield Nabel, Jason R Ruth, Sophia A T Parente, Daniel J Arenas, Mary Guilfoyle, Manjula Reddy, Michael Weinblatt, Nancy A Shadick, Mark Bower, Alessia Dalla Pria, Yasufumi Masaki, Laura Katz, Jason Mezey, Philip Beineke, David Lee, Craig Tendler, Taku Kambayashi, Alexander Fosså, Frits van Rhee, David C Fajgenbaum
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. Blood advances 5 (17) (2021)
Antonino Carbone, Margaret Borok, Blossom Damania, Annunziata Gloghini, Mark N Polizzotto, Raj K Jayanthan, David C Fajgenbaum, Mark Bower
Castleman disease. Nature reviews. Disease primers 7 (1) (2021)
Jung-Yeon Lim, Sascha H C Duttke, Turner S Baker, Jihye Lee, Kristyne J Gambino, Nicholas J Venturini, Jessica Sook Yuin Ho, Simin Zheng, Yesai S Fstkchyan, Vinodh Pillai, David C Fajgenbaum, Ivan Marazzi, Christopher W Benner, Minji Byun
DNMT3A haploinsufficiency causes dichotomous DNA methylation defects at enhancers in mature human immune cells. The Journal of experimental medicine 218 (7) (2021)
Yoshito Nishimura, David C Fajgenbaum, Sheila K Pierson, Noriko Iwaki, Asami Nishikori, Mitsuhiro Kawano, Naoya Nakamura, Koji Izutsu, Kengo Takeuchi, Midori Filiz Nishimura, Yoshinobu Maeda, Fumio Otsuka, Kazuyuki Yoshizaki, Eric Oksenhendler, Frits Van Rhee, Yasuharu Sato
Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. American journal of hematology 96 (10) (2021)
David C Fajgenbaum, Carl H June
Cytokine Storm. The New England journal of medicine 383 (23) (2020)
David C Fajgenbaum, David Wu, Aaron Goodman, Raymond Siu Ming Wong, Amy Chadburn, Sunita Nasta, Gordan Srkalovic, Sudipto Mukherjee, Heather Leitch, Raj Jayanthan, Simone Ferrero, Yasuharu Sato, Steve Schey, Angela Dispenzieri, Eric Oksenhendler, Pier Luigi Luigi Zinzani, Mary Jo Lechowicz, Christian Hoffmann, Naveen Pemmaraju, Adam Bagg, Alexander Fossa, Megan S Lim, Frits Van Rhee, null null
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. American journal of hematology 95 (12) (2020)
David C Fajgenbaum, Johnson S Khor, Alexander Gorzewski, Mark-Avery Tamakloe, Victoria Powers, Joseph J Kakkis, Mileva Repasky, Anne Taylor, Alexander Beschloss, Laura Hernandez-Miyares, Beatrice Go, Vivek Nimgaonkar, Madison S McCarthy, Casey J Kim, Ruth-Anne Langan Pai, Sarah Frankl, Philip Angelides, Joanna Jiang, Rozena Rasheed, Erin Napier, Duncan Mackay, Sheila K Pierson
Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review. Infectious diseases and therapy 9 (3) (2020)
Christopher S Nabel, Stephen Sameroff, Dustin Shilling, Daisy Alapat, Jason R Ruth, Mitsuhiro Kawano, Yasuharu Sato, Katie Stone, Signe Spetalen, Federico Valdivieso, Michael D Feldman, Amy Chadburn, Alexander Fosså, Frits van Rhee, W Ian Lipkin, David C Fajgenbaum
Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease. PloS one 14 (6) (2019)
Turner S Baker, Kristyne J Gambino, Lawrence Schriefer, Jung-Yeon Lim, Karyn Meltz Steinberg, David C Fajgenbaum, Alejandro Martín García-Sancho, Minji Byun
A novel FAS mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease. Blood advances 2 (21) (2019)
Lu Zhang, Ai-Lin Zhao, Ming-Hui Duan, Zhi-Yuan Li, Xin-Xin Cao, Jun Feng, Dao-Bin Zhou, Ding-Rong Zhong, David C Fajgenbaum, Jian Li
Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. Blood 133 (16) (2019)
Frits Van Rhee, Peter Voorhees, Angela Dispenzieri, Alexander Fosså, Gordan Srkalovic, Makoto Ide, Nikhil Munshi, Stephen Schey, Matthew Streetly, Sheila K Pierson, Helen L Partridge, Sudipto Mukherjee, Dustin Shilling, Katie Stone, Amy Greenway, Jason Ruth, Mary Jo Lechowicz, Shanmuganathan Chandrakasan, Raj Jayanthan, Elaine S Jaffe, Heather Leitch, Naveen Pemmaraju, Amy Chadburn, Megan S Lim, Kojo S Elenitoba-Johnson, Vera Krymskaya, Aaron Goodman, Christian Hoffmann, Pier Luigi Zinzani, Simone Ferrero, Louis Terriou, Yasuharu Sato, David Simpson, Raymond Siu Ming Wong, Jean-Francois Rossi, Sunita Nasta, Kazuyuki Yoshizaki, Razelle Kurzrock, Thomas S Uldrick, Corey Casper, Eric Oksenhendler, David C Fajgenbaum
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 132 (20) (2018)
Deanna E Morra, Sheila K Pierson, Dustin Shilling, Sepideh Nemat, Carlos Appiani, Mary Guilfoyle, Craig Tendler, Frits van Rhee, David C Fajgenbaum
Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. British journal of haematology 184 (2) (2018)
Sheila K Pierson, Aaron J Stonestrom, Dustin Shilling, Jason Ruth, Christopher S Nabel, Amrit Singh, Yue Ren, Katie Stone, Hongzhe Li, Frits van Rhee, David C Fajgenbaum
Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease. American journal of hematology 93 (7) (2018)

David C Fajgenbaum.css-eqlu8i{font-size:small;padding-left:4px;} (David Fajgenbaum)

Publication Activity (10 Years)

Top Topics

Top Venues

David C Fajgenbaum (David Fajgenbaum)